WEEKLY EPIDEMIOLOGY BULLETIN

NATIONAL SURVEILLANCE UNIT, MINISTRY OF HEALTH & WELLNESS, JAMAICA

Clostridium Tetani

Weekly Spotlight

Tetanus (Part 2)

Treatment

Tetanus is a medical emergency requiring:

- care in the hospital
- immediate treatment with medicine called human tetanus immune globulin (TIG)
- aggressive wound care
- drugs to control muscle spasms
- antibiotics
- tetanus vaccination.

People who recover from tetanus do not have natural immunity and can be infected again, and therefore need to be immunized.

Prevention

Tetanus can be prevented through immunization with tetanus-toxoid-containing vaccines (TTCV), which are included in routine immunization programmes globally and administered during antenatal care contacts.

To be protected throughout life, WHO recommends that an individual receives 6 doses (3 primary plus 3 booster doses) of TTCV. The 3-dose primary series should begin as early as 6 weeks of age, with subsequent doses given with a minimum interval of 4 weeks between doses. The 3 booster doses should preferably be given during the second year of life (12–23 months), at 4–7 years of age, and at 9–15 years of age. Ideally, there should be at least 4 years between booster doses.

There are many kinds of vaccines used to protect against tetanus, all of which are combined with vaccines for other diseases:

- diphtheria and tetanus (DT) vaccines
- diphtheria, tetanus, and pertussis (whooping cough) (DTaP) vaccines
- tetanus and diphtheria (Td) vaccines
- tetanus, diphtheria, and pertussis (Tdap) vaccines.

Neonatal tetanus can be prevented by immunizing women of reproductive age with TTCV, either during pregnancy or outside of pregnancy. Additionally, robust medical practices can also prevent tetanus disease including clean delivery and cord care during childbirth, and proper wound care for surgical and dental procedures. In countries where national programmes have maintained high immunization coverage for several decades, tetanus incidence rates are very low.

Taken from WHO website on 24/March/2025 https://www.who.int/news-room/fact-sheets/detail/tetanus Pictures taken from https://health.thefuntimesguide.com/getting-tetanus-shot/

EPI WEEK 11



Syndromic Surveillance

Accidents


Violence

Pages 2-4



Class 1 Notifiable Events

Page 5



COVID-19

Page 6



Influenza

Page 7



Dengue Fever

Page 8



Research Paper

Page 9

SENTINEL SYNDROMIC SURVEILLANCE

Sentinel Surveillance in Jamaica A syndromic surveillance system is good for early detection of and response to public health events.

Sentinel surveillance occurs when selected health facilities (sentinel sites) form a network that reports on certain health conditions on a regular basis, for example, weekly. Reporting is mandatory whether or not there are cases to report.

Jamaica's sentinel surveillance system concentrates on visits to sentinel sites for health events and syndromes of national importance which are reported weekly (see pages 2 -4). There are seventy-eight (78) reporting sentinel sites (hospitals and health centres) across Jamaica.



Table showcasing the Timeliness of Weekly Sentinel Surveillance Parish Reports for the Four Most Recent Epidemiological Weeks – 8 to 11 of 2025

Parish health departments submit reports weekly by 3 p.m. on Tuesdays. Reports submitted after 3 p.m. are considered late.

KEY:

Yellow- late submission on Tuesday

Red – late submission after Tuesday


Epi week	Kingston and Saint Andrew	Saint Thomas	Saint Catherine	Portland	Saint Mary	Saint Ann	Trelawny	Saint James	Hanover	Westmoreland	Saint Elizabeth	Manchester	Clarendon
						20)25						
8	On	On	On	On	On	On	On	On	On	On	On	On	On
	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time
9	On	On	On	On	On	On	On	On	On	On	On	On	On
	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time
10	On	On	On	On	On	On	On	On	On	On	On	On	On
	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time
11	On	On	On	On	On	On	On	On	On	On	On	On	On
	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time


REPORTS FOR SYNDROMIC SURVEILLANCE

UNDIFFERENTIATED FEVER

Temperature of $>38^{\circ}C$ /100.4°F (or recent history of fever) with or without an obvious diagnosis or focus of infection.









INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





FEVER AND NEUROLOGICAL

Temperature of >38°C /100.4°F (or recent history of fever) in a previously healthy person with or without headache and vomiting. The person must also have meningeal irritation, convulsions, altered consciousness, altered sensory manifestations or paralysis (except AFP).



FEVER AND HAEMORRHAGIC

Temperature of $>38^{\circ}C$ /100.4°F (or recent history of fever) in a previously healthy person presenting with at least one haemorrhagic (bleeding) manifestation with or without jaundice.




FEVER AND JAUNDICE


Temperature of $>38^{\circ}C/100.4^{\circ}F$ (or recent history of fever) in a previously healthy person presenting with jaundice.

The epidemic threshold is used to confirm the emergence of an epidemic in order to implement control measures. It is calculated using the mean reported cases per week plus 2 standard deviations.


Weekly Visits to Sentinel Sites for Fever and Neurological Symptoms 2024 and 2025 vs. Weekly Threshold: Jamaica



Weekly visits to Sentinel Sites for Fever and Haemorrhagic 2024 and 2025 vs Weekly Threshold; Jamaica



Fever and Jaundice cases: Jamaica, Weekly Threshold vs Cases 2024 and 2025





NOTIFICATIONS-All clinical sites



INVESTIGATION
REPORTS- Detailed Follow
up for all Class One Events




HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



ACCIDENTS

Any injury for which the cause is unintentional, e.g. motor vehicle, falls, burns, etc.





VIOLENCE

Any injury for which the cause is intentional, e.g. gunshot wounds, stab wounds, etc.




Weekly Visits to Sentinel Sites for Violence by Age Groups 2025 vs. Weekly **Threshold** 800 700 600 Number of Visits 500 400 300 200 100 n 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 Epidemiological Week ■<5 y.o Epi Threshold <5 y/o - Epi Threshold ≥5y/o

GASTROENTERITIS

Inflammation of the stomach and intestines, typically resulting from bacterial toxins or viral infection and causing vomiting and diarrhoea.









INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



CLASS ONE NOTIFIABLE EVENTS

Comments

			Confirm	ed YTD ^α	AFP Field Guides from	
	CLASS 1 E	VENTS	CURRENT YEAR 2025	PREVIOUS YEAR 2024	WHO indicate that for an effective surveillance system, detection rates for	
	Accidental P	oisoning	11 ^β	89 ^β	AFP should be 1/100,000 population under 15 years old (6 to 7) cases annually. ——————————————————————————————————	
亅	Cholera		0	0		
VON	Severe Deng	ue ^y	See Dengue page below	See Dengue page below		
ATI	COVID-19 (SARS-CoV-2)	38	153		
NATIONAL /INTERNATIONAL INTEREST	Hansen's Di	sease (Leprosy)	0	0		
L /INTERN INTEREST	Hepatitis B		0	11		
	Hepatitis C		0	2	—————— [→] Dengue Hemorrhagic	
√NO	HIV/AIDS		NA	NA	Fever data include Dengue	
ATI	Malaria (Im	ported)	0	0	related deaths;	
Z	Meningitis		2	6	δ Figures include all deaths	
	Monkeypox		0	0	associated with pregnancy	
EXOTIC/ UNUSUAL	Plague		0	0	reported for the period. ^ε CHIKV IgM positive case ^β Zika PCR positive cases ^β Updates made to prior weeks.	
14	Meningococ	cal Meningitis	0	0		
GH IDII ALL	Neonatal Ter	anus	0	0		
H IGH MORBIDITY/ MORTALITY	Typhoid Fev	er	0	0		
M	Meningitis H	I/Flu	0	0		
	AFP/Polio		0	0	 ^α Figures are cumulative totals for all epidemiological 	
	Congenital F	Rubella Syndrome	0	0	weeks year to date.	
	Congenital Syphilis		0	0		
MES	Fever and Rash	Measles	0	0		
KAMIN		Rubella	0	0		
[DO]	Maternal De	Maternal Deaths $^{\delta}$		12		
SPECIAL PROGRAMM	Ophthalmia l	Ophthalmia Neonatorum		38		
	Pertussis-like	e syndrome	0	0		
	Rheumatic F	'ever	0	0		
	Tetanus		0	0		
	Tuberculosis		0	15		
	Yellow Feve		0	0		
	Chikungunya	a^{ε}	0	0		
	Zika Virus ^θ		0	0	NA- Not Available	







INVESTIGATION REPORTS- Detailed Follow up for all Class One Events




HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



COVID-19 Surveillance Update

		COVID	
CASES	EW 11	Total	
Confirmed	7	157476	
Females	5	90732	
Males	2	66741	
Age Range	6 to 75 years	1 day to 108 years	

- * 3 positive cases had no gender specification
- * PCR or Antigen tests are used to confirm cases
- * Total represents all cases confirmed from 10 Mar 2020 to the current Epi-Week.




COVID-19 Outcomes


Outcomes	EW 11	Total
ACTIVE *2 weeks*		9
DIED – COVID Related	0	3875
Died - NON COVID	0	396
Died - Under Investigation	0	142
Recovered and discharged	0	103226
Repatriated	0	93
Total		157468

- *Vaccination programme March 2021 YTD
- * Total as at current Epi week


3311 COVID-19 Related Deaths since March 1, 2021 – YTD Vaccination Status among COVID-19 Deaths



COVID-19 Parish Distribution and Global Statistics



COVID-19 WHO Global Statistics EW 8 -11, 2025					
Epi Week	Confirmed Cases	Deaths			
8	36400	780			
9	32900	698			
10	22200	632			
11	13000	469			
Total (4weeks)	104500	2579			



6 NOTIFICATIONS-All clinical sites



INVESTIGATION
REPORTS- Detailed Follow
up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued




NATIONAL SURVEILLANCE UNIT **INFLUENZA REPORT**

EW 11

March 9, 2025 - March 15, 2025 Epidemiological Week 11

	EW 11	YTD
SARI cases	8	110
Total Influenza positive Samples	1	113
Influenza A	1	104
H1N1pdm09	1	68
H3N2	0	36
Not subtyped	0	0
Influenza B	0	9
B lineage not determined	0	0
B Victoria	0	9
Parainfluenza	0	0
Adenovirus	0	0
RSV	0	28




Weekly visits to Sentinel Sites for Influenza-like Illness (ILI) All ages

Epidemiological week

2025 < 5 ■ 2025 ≥60 Epidemic Threshold 5-59 2025 5-59 Epidemic Threshold <5 Epidemic Threshold ≥60

Epi Week Summary

During EW 11, eight (8) SARI admissions were reported.




Caribbean Update EW 11

Caribbean: Influenza activity remains high for ILI and decreasing for SARI. The predominant influenza subtype was reported to be A(H1N1)pdm09. RSV cases remain low. SARS-CoV-2 shows an increase in detection for ILI cases.

By country: Over the past 4 EW, influenza activity has increased in Belize, the Dominican Republic and Jamaica, while decreasing in Suriname, Saint Lucia, Barbados, Guyana and Saint Lucia and Saint Vincent and the Grenadines. An increase in RSV activity was observed in Jamaica, Saint Lucia and Suriname as well as an increase in SARS-CoV-2 detection in Jamaica and Guyana.

(taken from PAHO Respiratory viruses weekly report)

Distribution of Influenza and Other Respiratory Viruses Under



https://www.paho.org/en/influenza-situation-report





INVESTIGATION **REPORTS-** Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued




Dengue Bulletin

March 9, 2024 - March 15, 2025 Epidemiological Week 11



Epidemiological Week 11



Reported suspected, probable and confirmed dengue with symptom onset in week 11 of 2025


	2025*		
	EW 11	YTD	
Total Suspected, Probable & Confirmed Dengue Cases	2	104	
Lab Confirmed Dengue cases	0	0	
CONFIRMED Dengue Related Deaths	0	0	

Symptoms of Dengue fever Febrile phase Critical phase sudden-onset fever hypotension headache pleural effusion mouth and nose ascites bleeding gastrointestinal bleeding muscle and joint pains Recovery phase altered level of vomiting consciousness seizures rash itching diarrhea slow heart rate

Points to note:

- Dengue deaths are reported based on date of death.
- *Figure as at, March 28, 2025
- Only PCR positive dengue cases are reported as confirmed.
- IgM positive cases are classified as presumed dengue.

Suspected, probable and confirmed dengue cases for 2023-2025 versus monthly mean, alert and epidemic threshold (2007-2022)



NOTIFICATIONS-All clinical sites



INVESTIGATION
REPORTS- Detailed Follow
up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





RESEARCH PAPER

Abstract

NHRC-23-008

The effects of semi-purified fractions from *Plectranthus blumei* (Joseph Coat) in normal healthy Sprague-Dawley rats.

Gordon A and Alexander-Lindo R

The University of the West Indies, Mona Campus, Kingston 7, Jamaica.

Objective: To investigate the effects of semi-purified fractions from ethyl acetate crude extract of *Plectranthus blumei* (Joseph Coat) on blood glucose levels in normal, healthy Sprague-Dawley rats.

Method: Ethyl acetate crude extract was obtained and purified using chromatographic techniques. The fractions AG/A-AG/J were collected and grouped according to similar TLC profiles and the active hypoglycaemic fraction AG/F was further purified to obtain sub-fractions AG/F1-AG/F6 which were bioassayed using the Oral Glucose Tolerance Test (OGTT). A fasting blood glucose reading was obtained followed by intravenous administration of the semi-purified fractions (30 mg/kg body weight (BW), 20 mg/kg BW) versus the control dimethyl sulfoxide (DMSO).

Results: At 30 mg/kg BW the fraction AG/F showed the most significant hypoglycaemic activity throughout the entire OGTT. Hypoglycaemic activity was observed at time intervals 30 minute (3.09 \pm 0.52 mmol/L vs 6.01 \pm 0.29 mmol/L; P = 0.001); 90 minute (5.22 \pm 0.26 mmol/L vs 7.49 \pm 0.61 mmol/L; P = 0.006) when compared with the control DMSO. The subfractions AG/F1-AG/F6 were administered intravenously at 20 mg/kg BW where fraction AG/F5 showed the most hypoglycaemic activity. Significant lowering was observed throughout the experiment at time intervals 60 minute (2.62 \pm 0.60 mmol/L vs 5.69 \pm 0.23 mmol/L; P = 0.004); 120 minute (3.86 \pm 0.85 mmol/L vs 6.43 \pm 0.47 mmol/L; P = 0.022) when compared with DMSO. The subfractions AG/F indicated compounds which are fatty acids and phenolic in nature.

Conclusion: Bioassay-guided purification of the ethyl acetate crude extract resulted in sub-fractions showing hypoglycaemic capabilities.



The Ministry of Health and Wellness *15 Knutsford Boulevard*, Kingston 5, Jamaica Tele: (876) 633-7924

Email: surveillance@moh.gov.jm



NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued

